HC006

Phase 1Small molecule

HHC Biopharma Inc.

HC006 is one of 87 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorsRecruiting

Patients With Advanced Solid TumorsRecruiting

Advanced Solid TumorsPhase 1

Recruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

286 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

24 2

Paraplatin

AAvyxa

Phase 2

31 3

Abraxane

Bristol-Myers Squibb

Phase 2

10 4

Taxotere

AAvyxa

Phase 2

23 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

19 6

Ibrance

Pfizer

Phase 2

4 7

Erbitux

IImclone

Phase 2

14 8

Tagrisso

AstraZeneca

Phase 2

3 9

Mektovi

Pfizer

Phase 2

3 10

Alimta

SShawn Eagle

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Patients With Advanced Solid Tumors

NCT06963814

Q1 2028

Phase 1Recruiting

Advanced Solid Tumors

NCT07477743

Clinical

Trials by Indication[1]

Advanced Solid Tumors2 trials

A Study of HC006 in Subjects With Advanced Solid Tumors

Recruiting·HHC Biopharma Inc.·Phase 1·NCT06304571·76 enrolled

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors

Recruiting·HHC Biopharma Inc.·Phase 1·NCT07477743·331 enrolled

Patients With Advanced Solid Tumors1 trial

Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors

Recruiting·HHC Biopharma Inc.·Phase 1·NCT06963814·252 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HC006. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HC006 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HC006. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HC Biopharma Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHC Biopharma Inc.

HC006

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Trials by Indication[1]

Advanced Solid Tumors2 trials

Patients With Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News